Array BioPharma announces BRAFTOVI + MEKTOVI + cetuximab neet primary endpoints
Array BioPharma announced positive results from the interim analysis of the Phase 3 BEACON CRC trial evaluating the combination of BRAFTOVI® (encorafenib), MEKTOVI® (binimetinib), and ERBITUX® (cetuximab) in patients with BRAFV600E-mutant mCRC, following one or two prior lines of therapy. May 21, 2019